Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: reduction of erythropoietin dose in 4 years of follow-up

BACKGROUND: Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have be...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Kidney Res Clin Pract
Autores principales: Lacquaniti, Antonio, Pasqualetti, Patrizio, Tocco, Teresa Casuscelli di, Campo, Susanna, Rovito, Stefania, Bucca, Maurizio, Ragusa, Antonino, Monardo, Paolo
Formato: Artigo
Lenguaje:Inglês
Publicado: Korean Society of Nephrology 2020
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7530360/
https://ncbi.nlm.nih.gov/pubmed/32839355
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.23876/j.krcp.20.015
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares